Low-dose influenza vaccine Grippol Quadrivalent with adjuvant Polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity

Talayev, V.Yu.; Zaichenko, I.Ye.; Svetlova, M.V.; Матвеичев, А В; Babaykina, O.N.; Voronina, E.V.; Миронов, А. Ю.

doi:10.1016/j.vaccine.2020.07.053

Cited by 15 publications

(12 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AZB also inhibits the accumulation of the myeloid-derived suppressor cells (MDSCs) in conditions of experimental aseptic inflammation as well as reducing extracellular neutrophil trap formation in in vitro studies (53,54). It enhances the expression of the inducible costimulatory-ligand (ICOS-L) molecule by 1.7fold and increases the ability of dendritic cells to stimulate the maturation of follicular helper T-lymphocytes and enhances the T-dependent humoral response (55,56). In short, AZB displays properties of a drug that might be expected to have direct antitumor effects.…”

Section: Clinical Promise Beyond Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Azoximer Bromide: Mystery, Serendipity, and Promise

2021

View full text Add to dashboard Cite

Azoximer bromide (AZB) was identified as an immunomodulator, and was initially developed and currently successfully indicated as one of several natural polyelectrolytes, a vaccine adjuvant, and an effective agent for the treatment of infectious and inflammatory diseases of viral, bacterial, and fungal origin. AZB has the potential to increase an individual’s resistance to local and general infection and is indicated for the treatment of viral infections, and has also demonstrated clinical efficacy in the treatment of a variety of secondary immunodeficiencies. However, AZB may offer long-term promise beyond use against infection. Multiple clinical trials and research studies in cancer patients have reported favourable outcomes with AZB as well as an optimal safety and tolerability profile. The findings raise the possibility of direct antitumor properties. This literature review analyses the novel mechanisms that mediate the AZB direct anticancer effects. Overall, the evidence suggests that AZB has the hallmark of an agent that could be used to support existing cancer treatments at different stages of disease.

show abstract

Section: Clinical Promise Beyond Infectionmentioning

confidence: 99%

“…Another property of AZB is its ability to reduce the level of NET formation in experimental studies in vitro (45). Moreover, it was shown that AZB leads to the secretion of cytokines by T-helper 2 (TH-2) cells, including interleukin-5 (IL-5) (27,55,56). AZB has a complex effect on the immune system.…”

Section: Clinical Promise Beyond Infectionmentioning

confidence: 99%

Azoximer Bromide: Mystery, Serendipity, and Promise

2021

View full text Add to dashboard Cite

show abstract

“…В исследованиях V. Talayev с соавт. [29] при изучении особенностей развития иммунного ответа на вакцину GQ определяли вклад адъюванта в этот ответ при иммунизации мышей BALB/c вакциной или смесями АГ, не содержащими адъюванта [29]. Отмечается, что вакцина GQ является иммуногенной при использовании низкой дозы АГ, индуцирует Th2-поляризованный Т-клеточный ответ и созревание CD4 + Т-клеток памяти, активирует выработку АТ к гемагглютининам четырех штаммов вируса гриппа и увеличивает активность NK-клеток.…”

Section: полиоксидонийunclassified

“…Авторы отмечают, что выраженного ответа Th1 и ответа CD8 + Т-клеток при введении вакцины не наблюдалось. В условиях in vitro вакцина стимулировала созревание ДК человека, повышая экспрессию молекул HLA-DR, CD80, CD83, CD86 и ICOSL [29].…”

Section: полиоксидонийunclassified

General characteristics of adjuvants and their mechanisms of action (part 2)

Алпатова¹,

Авдеева²,

Лысикова³

et al. 2021

Biological Products. Prevention, Diagnosis, Treatment

View full text Add to dashboard Cite

One of the major public health challenges today is development of new vaccines and technologies to optimize the vaccination process. There is a growing scientific interest in vaccine adjuvants that enhance vaccine immunogenicity. At present, numerous studies are underway to develop COVID-19 vaccines, including inactivated and subunit vaccines which contain adjuvants for efficient induction of immune response and solid immunity. The aim of the study was to systematise literature related to the analysis of the structure, mechanisms of action and stimulating properties of vaccine adjuvants (synthetic oligodeoxynucleotides, virosomes, polyoxidonium, sovidone), as well as to summarise data on the effects of adjuvants used in SARS-CoV, MERS-CoV, and SARS-CoV-2 vaccine development studies. The paper analyses the prospects for enhancing the stimulating effect of the adjuvants when used in combination with compounds having a different mechanism of action. It also analyses the results of studies of adjuvanted vaccines against SARS-CoV and MERS-CoV, which may be useful when selecting adjuvants with optimal efficacy and safety profiles to be used in SARS-CoV-2 vaccines under development. It was concluded that understanding of the mechanisms of action of adjuvants that mediate their stimulating effect on the body’s immune system will contribute to safe and effective use of adjuvants to enhance the immunogenicity of both authorised and new vaccines.

show abstract

“…[20][21][22] In the Grippol formulations, AZB allows a reduction in the amount of HA antigen required per dose. 23 This antigen-sparing strategy raises two questions:…”

Section: Introductionmentioning

confidence: 99%

Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.

Kompier¹,

Neels²,

Beyer³

et al. 2022

F1000Res

View full text Add to dashboard Cite

A systematic review of clinical trials conducted with a low-dose inactivated influenza vaccine adjuvanted by azoximer bromide (AZB, Polyoxidonium), was performed to compare vaccine reactogenicity against non-adjuvant vaccines. We also assessed whether lower amounts of antigen per viral strain in AZB-adjuvanted vaccines affected antibody responses. A robust search strategy identified scientific publications reporting 30 clinical trials, comprising data on 11,736 participants and 86 trial arms, for inclusion in the analysis. Local reaction rates (Rlr) appeared to be lower in AZB-adjuvanted vaccine treatment arms versus comparator vaccine treatment arms. Meta‑regression analysis revealed that AZB did not contribute to vaccine reactogenicity. Post-vaccination geometric mean titres in those exposed to AZB-adjuvanted vaccine and comparator vaccine treatment arms were similar in both children and adults aged 18–60 years, implying an antigen-sparing effect by AZB.

show abstract

Low-dose influenza vaccine Grippol Quadrivalent with adjuvant Polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity

Cited by 15 publications

References 51 publications

Azoximer Bromide: Mystery, Serendipity, and Promise

Azoximer Bromide: Mystery, Serendipity, and Promise

General characteristics of adjuvants and their mechanisms of action (part 2)

Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.

Contact Info

Product

Resources

About